Clinical bottom line
Radiation-induced peripheral vascular injury (RIPVI) is an under-recognized complication of radiotherapy that can lead to significant morbidity, including ischemia and tissue necrosis. Emerging evidence suggests that AI-enhanced imaging modalities may facilitate earlier detection of RIPVI by identifying subtle vascular changes before clinical symptoms arise. While current data are preliminary and largely extrapolated from related vascular and radiation injury imaging studies, AI-driven analysis of vascular imaging holds promise for improving risk stratification and guiding timely interventions in patients undergoing radiation therapy.
What the evidence shows
Radiation therapy can induce progressive damage to peripheral blood vessels, manifesting as endothelial dysfunction, fibrosis, and occlusive disease (Rosen et al., year unknown). Early detection of these vascular changes is challenging with conventional imaging due to subtlety and nonspecificity of findings. AI-enhanced imaging approaches, leveraging advanced pattern recognition and quantitative analysis, have demonstrated potential in related contexts such as radiation-induced cardiac injury (Zhang et al., 2018) and lung injury (Wang et al., 2025).
Although direct studies on RIPVI are limited, the principles established in these adjacent fields support the hypothesis that AI algorithms can detect early vascular remodeling and perfusion abnormalities. For example, AI models trained on CT and MR angiography data may identify early luminal narrowing or wall thickening indicative of radiation injury before overt stenosis develops. This approach parallels AI applications in early detection of radiation-induced organ injuries, where subtle imaging biomarkers are extracted beyond human visual acuity (Wang et al., 2025; Zhang et al., 2018).
Furthermore, AI integration with wearable biosignal monitoring and digital twin technologies has been proposed to enhance vascular injury surveillance, although these remain largely experimental (Ranjana et al., 2025). The translational gap from preclinical models to clinical practice persists, underscoring the need for prospective validation.
Caveats and uncertainty
The evidence base for AI-enhanced imaging specifically targeting RIPVI is currently sparse and largely inferential. Most cited studies focus on radiation-induced injury in other organs or on peripheral vascular disease without radiation context (Rosen et al.). There is a lack of large-scale, prospective clinical trials validating AI algorithms for early RIPVI detection.
Additionally, variability in radiation dose, treatment field, and patient comorbidities complicates standardization of imaging biomarkers. AI models require extensive, high-quality annotated datasets for training and validation, which are currently limited for this indication. The risk of false positives and overdiagnosis also warrants caution, as does the integration of AI findings into clinical decision-making pathways.
Finally, the clinical impact of earlier detection on patient outcomes remains unproven. It is unclear whether earlier identification of subclinical vascular injury will translate into effective preventive or therapeutic interventions.
How this may change practice
If validated, AI-enhanced imaging could become a valuable adjunct in the surveillance of patients receiving radiation therapy, enabling earlier identification of peripheral vascular injury and potentially reducing downstream complications. Radiologists may incorporate AI tools to quantitatively assess vascular morphology and perfusion changes on routine follow-up imaging.
This approach could facilitate personalized radiation planning by identifying patients at higher risk for vascular toxicity, prompting dose modification or protective strategies. Additionally, AI-driven detection might guide timely referral to vascular specialists for preventive management.
However, widespread clinical adoption will require robust evidence demonstrating improved diagnostic accuracy, cost-effectiveness, and impact on clinical outcomes. Multidisciplinary collaboration will be essential to integrate AI findings into comprehensive patient care pathways.